# Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/capivasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Peter Schmid,Jacinta Abraham,Stephen Chan,Duncan Wheatley,Adrian Murray Brunt,Gia Nemsadze,Richard D. Baird,Yeon Hee Park,Peter S Hall,Timothy Perren,Robert C. Stein,László Mangel,Jean-­Marc Ferrero,Melissa Phillips,John Conibear,Javier Cortés,Andrew Foxley,Elza C. de Bruin,Robert McEwen,Daniel Stetson,Brian Dougherty,Shah‐Jalal Sarker,Aaron Prendergast,Max McLaughlin-Callan,Matthew Burgess,Cheryl Lawrence,Hayley Cartwright,Kelly Mousa,Nicholas C. Turner |
| Citations | 393 |
| DOI | 10.1200/jco.19.00368 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.19.00368 |
| OpenAlex ID | https://openalex.org/W2996625978 |
| PMID | 31841354 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Shah‐Jalal Sarker](https://scholariq.org/researchers/shah-jalal-sarker/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

## Paper topics

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.